ARMS-qPCR Improves Detection Sensitivity of Earlier Diagnosis of Papillary Thyroid Cancers with Worse Prognosis Determined by BRAF V600E and TERT Promoter Co-existing Mutations
Peng-Cheng Yu 1, Li-Cheng Tan 1, Xiao-Li Zhu 2, Xiao Shi 1, Roman Chernikov 3, Arseny Semenov 3, Ling Zhang 2, Ben Ma 1, Yu Wang 1, Xiao-Yan Zhou 2, Qing-Hai Ji 1, Wen-Jun Wei 4, Yu-Long Wang

In conclusion, patients with co-existing BRAF V600E and TERT promoter mutation have a worse prognosis. ARMS-qPCR,the more sensitive method, can be used to identify the early stages of patients with a potentially worse prognosis

Endocr Pract. 2021 Jan 27;S1530-891X(21)00021-5.

Sensitive Detection of KRAS Mutations by Clustered Regularly Interspaced Short Palindromic Repeats
Huifen Zhou,† Jen-Hui Tsou,† Qixin Leng, and Feng Jiang

Testing for activating KRAS mutations has important implications for diagnosis and the personalized medicine of cancers.

Diagnostics (Basel). 2021 Jan; 11(1): 125.

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
Hisashi Tanaka 1, Kageaki Taima 1, Tomonori Makiguchi 1, Junichi Nakagawa 2, Takenori Niioka 2, Sadatomo Tasaka

Here, we present the case of a 56-year-old man who was diagnosed with lung adenocarcinoma with MET exon 14 skipping mutation.

Cancer Commun. 2021 Jan 2. 

Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer
GuanShaoxinga ChenXib XinShuang LiuShuabYangYunpeng FangWenfeng HuangYan ZhaoHongyun ZhuXia ZhuangWei WangFei FengWei ZhangXiaoxu HuangMin WangXueding ZhangLi

Our finding demonstrated that the incidence, not the severity, of gefitinib-induced rash predicted improved survival, the gefitinib concentration and polymorphisms of SLC22A8 and SLC22A1 were recommended to manage severe rash.

Transl Oncol. 2020 Nov 19;14(1):100951. 

Tumor-infiltrating CD8+ T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells
Chenxi Zeng, Yi Gao, Jing Xiong, Jiawei Lu, Jianjian Yang, Xue Wang, Yixin Cai, Lequn Li, Xiangning Fu

the ALK-positive tumor microenvironment suppresses the immune function of tumor-infiltrating CD8+ T cells through a PD-1/PD-L1-independent mechanism, which might lead to the inability of ALK-positive tumors to respond to PD-1/PD-L1-based immunotherapy.

Lung Cancer. 2020 Oct 21;150:139-144. 

Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients
Xiaojing Xu, Yiyi Yu, Minna Shen, Mengling Liu, Shengchao Wu, Li Liang, Fei Huang, Chenlu Zhang, Wei Guo, Tianshu Liu

Analyzing mutations in plasma could provide a more comprehensive overview of the mutational landscape than analyzing mutations in tissue. The cfDNA concentration could be a quantitative biomarker of tumor burden and could predict survival in Chinese patients with mCRC

BMC Cancer. 2020 Oct 16;20(1):1006.